Foghorn Therapeutics Q2 net loss narrows to $7.2 million from $17.9 million
Foghorn Therapeutics reported second quarter 2026 results, with collaboration revenue rising to $16.1 million and net loss narrowing to $7.2 million from $17.9 million a year earlier. Revenue was boosted by a $14.2 million cumulative catch-up adjustment tied to the December 2026 expiration of the Lilly research term, and the company said the CBPd-171 timeline has been delayed by an operational issue at a third-party contract research organization.
Key points
- Collaboration revenue was $16.1 million for the quarter ended June 30, 2026, up from $7.6 million, including a $14.2 million cumulative catch-up adjustment.
- Research and development expenses fell to $18.5 million from $21.8 million, and general and administrative expenses fell to $6.4 million from $6.9 million.
- Cash, cash equivalents and marketable securities were $167.6 million as of June 30, 2026, with cash runway into the first half of 2028.
- The CBPd-171 timeline was delayed; the company will provide updated guidance once available.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.